Gold era of crypto? Tokenized metals reach ATH of $3.6 billion
The value of tokenized gold has exploded over the past few months, driven by both adoption and rising macroeconomic risks.
- Tokenized gold reached an all-time high at $3.6 billion
- Tether’s XAUT and PAX Gold dominate the tokenized gold market
- Gold on the blockchain rose 50x in value since 2021
- Macroeconomic uncertainty is driving the appeal of tokenized gold
With economic uncertainty driving the price of gold higher, the interest in tokenized gold is growing. On Wednesday, November 12, the value of tokenized gold reached an all-time high of $3.6 billion, according to data from Token Terminal. What is more, this figure is 50 times higher than it was in 2021.
The largest tokenized precious metal asset is Tether Gold (XAUT) , with a market cap of $1.58 billion. PAX Gold is in second place, valued at $1.39 billion. Together, these assets dominate the market, with other players holding a minor part of the market share.
Macro uncertainty drives demand for tokenized gold
Interest in tokenized gold is coming from both the adoption of tokenized assets and rising demand for investment in precious metals. Historically, gold has risen when other assets, including equities, bonds, and crypto, have fallen. For that reason, traders hold gold to hedge against systemic risk in the global markets.
Notably, rising macroeconomic uncertainty, driven by global trade disruptions, government debt, and inflation fears, is prompting investors to seek safe havens. Namely, gold reached its all-time high of $4,381 in October 2025, during the escalation of the trade war between the U.S. and China.
Still, tokenized gold accounts for a minuscule share of the overall gold market. Current estimates state that the world’s above-ground gold reserves amount to 216,265 metric tonnes. At current prices, the value of these reserves is $29.153 trillion , far above the $3.54 trillion crypto market cap.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP News Today: SEC Approves Altcoin ETFs, Boosting Institutional Investment in Cryptocurrency
- SEC approves multiple XRP/DOGE ETFs from 21Shares, Franklin Templeton, and Grayscale, signaling growing institutional acceptance of altcoins. - 21Shares' TOXR ETF gains automatic approval via CME CF XRP-Dollar tracking, with Coinbase and BNY Mellon handling custody/admin functions. - Franklin Templeton's XRP Trust removes restrictive clauses to accelerate listing, offering regulated exposure without custody risks from ledger forks. - Grayscale expands crypto offerings with XRP/DOGE ETFs on NYSE, joining
Germany's Solar Turning Point: Spotlight on Legislation, Infrastructure, and Ideological Differences
- Germany's SolarPlus Forum 2025 emphasized legislative clarity, funding innovation, and cross-sector collaboration to accelerate solar adoption amid evolving energy policies. - Outdated regulations and permitting hurdles were highlighted as barriers, with calls to align Bundestag reforms with market demands like gas surcharge removal by 2026. - Cement industry growth (5.7% CAGR) and green innovations support infrastructure needs, though energy cost volatility and compliance challenges persist. - Internati
Polkadot Latest Updates: ECB Raises Concerns: Cryptocurrency and Stock Market Downturns Resemble Dot-Com Bubble Threats
- ECB warns U.S. equity/crypto corrections threaten stability, urging central banks to retain rate-cut flexibility amid market volatility. - JPMorgan links crypto ETF outflows to retail investor behavior, noting $4B November sales contrast with $96B equity ETF inflows. - U.S. Treasury downplays recession risks, citing 2026 growth optimism despite shutdown impacts and services-driven inflation. - MSCI highlights tech valuation risks akin to dot-com era, while DeFi faces $12B liquidity crisis with 95% capita
Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats
- Novartis raised 2030 sales growth targets to 5-6% annually, driven by high peak sales expectations for oncology drugs Kisqali and Scemblix. - CEO Vas Narasimhan highlighted eight de-risked drugs with $3-10B peak potential, but analysts warned of patent expirations and uncertain pipeline progress beyond 2030. - Shares rose 0.5% post-announcement, while Exact Sciences surged 17% on its $105/share acquisition by Abbott and Samsung Biologics saw a 71% valuation re-rating after spin-off. - J.P. Morgan caution
Trending news
MoreCrypto prices
More
